Euglycemic diabetic ketoacidosis (DKA) is a serious and potentially life-threatening complication of diabetes mellitus. It is characterized by the presence of ketone bodies in the blood along with hyperglycemia and acidosis. Although the exact cause of euglycemic DKA is not known, it is believed to be related to an imbalance in the body's ability to produce and use insulin. In this article, we will discuss how to break the cycle of euglycemic DKA and achieve lasting control.
Euglycemic DKA is a type of DKA in which the blood glucose levels are elevated but not at a level that would normally be considered diabetic. It is often referred to as “silent DKA” because it is not usually associated with the traditional symptoms of DKA such as polyuria and polydipsia. It is more common in type 2 diabetes but can occur in type 1 as well. The most common cause of euglycemic DKA is an imbalance in the body's ability to produce and use insulin. This can be due to a variety of factors such as changes in medication, insulin resistance, or a lack of adherence to a diabetes management plan. It can also be caused by a sudden increase in physical activity or stress.
Euglycemic DKA can be difficult to diagnose because the symptoms may not be as pronounced as with traditional DKA. It is important to be aware of the signs and symptoms of euglycemic DKA so that it can be identified and treated as soon as possible. The most common symptoms of euglycemic DKA include: • Elevated blood glucose levels • Ketone bodies in the urine • Abnormal blood acidity • Nausea and vomiting • Abdominal pain • Fatigue If any of these symptoms are present, it is important to seek medical attention as soon as possible.
The goal of treating euglycemic DKA is to reduce the risk of further complications and restore normal blood glucose levels. Treatment typically involves a combination of medications, lifestyle changes, and close monitoring of blood glucose levels. Medications: Medications such as insulin, sulfonylureas, and thiazolidinediones can be used to help control blood glucose levels. Lifestyle Changes: Making healthy lifestyle changes such as eating a balanced diet, exercising regularly, and getting enough sleep can help to reduce the risk of euglycemic DKA. Monitoring: Regular monitoring of blood glucose levels is essential for managing euglycemic DKA.
The best way to prevent euglycemic DKA is to maintain good control of your diabetes. This means following your doctor's instructions for taking medications, eating a healthy diet, exercising regularly, and monitoring your blood glucose levels. It is also important to be aware of the signs and symptoms of euglycemic DKA and to seek medical attention if they are present.
Euglycemic DKA is a serious and potentially life-threatening complication of diabetes mellitus. It is important to be aware of the signs and symptoms of euglycemic DKA and to seek medical attention if they are present. Treatment typically involves a combination of medications, lifestyle changes, and close monitoring of blood glucose levels. The best way to prevent euglycemic DKA is to maintain good control of your diabetes.
1.
Q&A: When will individuals be able to receive customized cancer vaccines?
2.
Canadian Group Calls for Earlier Colorectal Cancer Screening
3.
Children living near oil and gas wells face higher risk of rare leukemia, studies show
4.
Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.
5.
Talquetamab Combos Show Survival Benefit in r/r Myeloma
1.
Liquid Biopsy: A Revolutionary Tool for Early Detection and Monitoring of Colorectal Cancer
2.
Clinical Pharmacology of Megakaryocyte Maturation-Targeted Therapeutics
3.
The Benefits and Side Effects of Bortezomib in the Fight Against Cancer
4.
Personalized Tumor Ecological Landscapes in Oncology
5.
Unmasking the Subtle Symptoms of Colon Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Immunotherapy: A New Era in Cancer Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation